Your Article Summary
Utility of Adiponectin as a Biomarker Predictive of Glycemic Efficacy Is Demonstrated by Collaborative Pooling of Data From Clinical Trials Conducted by Multiple Sponsors
Clinical Pharmacology & Therapeutics, 06/25/09
Wagner JA et al. - These analyses confirm previously demonstrated relationships between adiponectin levels and metabolic parameters and support the robust predictive utility of adiponectin across the spectrum of glucose tolerance. Cross-company precompetitive collaboration is a feasible and powerful approach to biomarker qualification.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Amgen, 12/11/09
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09
Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09

See Latest Articles